STOCK TITAN

Transcode Therapeutics Inc - RNAZ STOCK NEWS

Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.

TransCode Therapeutics Inc (RNAZ) is a clinical-stage biopharmaceutical company pioneering RNA-based therapies for metastatic cancers through its proprietary TTX nanoparticle delivery platform. This news hub provides investors and researchers with essential updates on the company’s progress in developing targeted treatments, including its lead candidate TTX-MC138 designed to inhibit metastasis-driving microRNA-10b.

Our curated collection offers immediate access to official press releases, clinical trial milestones, and strategic partnership announcements. Users will find updates spanning multiple critical areas: TTX platform advancements, regulatory submissions, financial disclosures, and peer-reviewed research collaborations in oncology.

Key content includes developments around the company’s nanoparticle delivery system, trial results for metastatic cancer therapies, and analyses of RNAZ’s position within the competitive oncology therapeutics market. All materials are sourced directly from company filings and verified industry publications to ensure reliability.

Bookmark this page for streamlined tracking of TransCode’s innovations in RNA oncology. Check regularly for new insights into how the company’s cutting-edge approach to metastatic disease treatment continues to evolve through clinical validation and strategic execution.

Rhea-AI Summary

TransCode Therapeutics (Nasdaq: RNAZ) announced the sale of 60 shares of its Series A Convertible Preferred Stock to Triton Funds for $500,000. Each share has a stated value of $10,000 and is convertible at a price of $0.60 per share of common stock. This offering is part of a registered direct offering under a previously effective Form S-3 registration statement filed with the SEC. The securities will not be offered in jurisdictions where it would be unlawful prior to proper registration.

TransCode aims to improve cancer treatment through its RNA therapeutic platform, including candidates targeting various tumor types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
Rhea-AI Summary

TransCode Therapeutics (NASDAQ: RNAZ) reported strong 2022 results, highlighting FDA approval for its Phase 0 clinical trial of TTX-MC138 in advanced solid tumors. Key milestones included a strategic alliance with MD Anderson Cancer Center and receiving Orphan Drug Designation for TTX-siPDL1. Financially, the company faced challenges, ending 2022 with $5.0 million in cash, down from $20.8 million in 2021. Research and development expenses rose to $10.5 million. Recent advancements include positive preclinical results for TTX-MC138, where 40% of treated animals showed complete response.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
Rhea-AI Summary

TransCode Therapeutics (NASDAQ: RNAZ) announced that the FDA granted Orphan Drug Designation for its lead candidate, TTX-MC138, aimed at treating pancreatic cancer. This designation is crucial due to pancreatic cancer's low survival rate, less than 10%. The designation may offer benefits such as seven years of marketing exclusivity, tax credits for qualified R&D, and an exemption from the PDUFA filing fee, estimated to save over $3 million. TTX-MC138 showed promise in preclinical models, achieving complete responses in 40% of subjects. A Phase 0 clinical trial is set to assess TTX-MC138 in patients with advanced solid tumors, aiming to inform future treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
Rhea-AI Summary

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has signed a non-binding letter of intent and a joint research and development agreement with BRAIN Biotech AG to co-develop a platform technology aimed at cancer treatment. The partnership focuses on integrating BRAIN's G-dase E CRISPR nuclease with TransCode's TTX nucleic acid delivery platform. This innovative approach targets cancer cells based on RNA biomarkers, potentially leading to new therapeutic applications. The collaboration is considered a significant milestone for TransCode, expanding its pipeline and enhancing its methodologies for treating metastatic cancer, which causes a majority of cancer-related deaths globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) announced a registered direct offering of 2,846,300 shares at $0.527 per share, aiming to raise approximately $1.5 million in gross proceeds. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around February 17, 2023, subject to standard conditions. The shares are being offered via a previously filed shelf registration statement with the SEC. This capital raise is intended to support the development of TransCode's RNA therapeutic candidates targeting various cancer types, including metastatic cancers, which are responsible for significant cancer mortality worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.78%
Tags
-
Rhea-AI Summary

TransCode Therapeutics (Nasdaq: RNAZ) announced successful preclinical proof-of-mechanism studies for its immunotherapy candidate, TTX-RIGA, in melanoma, designed to activate innate immunity via RIG-I receptor binding. The studies showed promising results in delivering RNA-based agonists to tumors, potentially enabling tumor-selective immune responses. The company plans to advance TTX-RIGA to animal studies in February 2023. Furthermore, FDA has authorized a Phase 0 clinical trial for another candidate, TTX-MC138, targeting microRNA-10b in advanced solid tumors, with patient enrollment expected soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.98%
Tags
Rhea-AI Summary

TransCode Therapeutics (NASDAQ: RNAZ) has received FDA authorization to commence its First-in-Human (FIH) Phase 0 clinical trial for TTX-MC138, targeting advanced solid tumors in up to 12 cancer patients. TTX-MC138 aims to inhibit microRNA-10b, a key player in metastasis. The trial will assess the delivery of the therapeutic to metastatic lesions and gather crucial pharmacokinetic data. Preclinical results indicate TTX-MC138's potential effectiveness in various cancers, demonstrating complete responses in animal studies. This marks a significant advancement for TransCode as a clinical-stage oncology company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
-
Rhea-AI Summary

TransCode Therapeutics (NASDAQ: RNAZ) has withdrawn its Registration Statement on Form S-1, initially filed on November 28, 2022, due to unfavorable market conditions. The Company believes these conditions do not align with the best interests of its stockholders for a public offering. TransCode focuses on RNA-based cancer treatments, aiming to improve patient outcomes with its therapeutic candidates targeting various tumor types. Their lead candidate, TTX-MC138, aims to treat metastatic cancer, a leading cause of cancer deaths worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
133.33%
Tags
none
-
Rhea-AI Summary

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an exploratory eIND application to the FDA for a First-in-Human Phase 0 clinical trial of TTX-MC138, targeting advanced solid tumors. This therapeutic aims to inhibit microRNA-10b, a key player in metastasis. The trial will involve up to 12 patients to assess the safety and pharmacokinetics of TTX-MC138. Successful results could pave the way for further clinical trials and potential treatments for aggressive cancers like breast and pancreatic cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
Rhea-AI Summary

TransCode Therapeutics (NASDAQ: RNAZ) reported Q3 2022 financial results, highlighting significant advancements in its RNA oncology pipeline. The company remains on schedule to submit an exploratory IND application for a Phase 0 trial involving TTX-MC138 in advanced solid tumors. Recently granted orphan drug designation for TTX-siPDL1 for pancreatic cancer emphasizes its focus on high-need areas. Financially, cash reserves decreased to $8.8 million, while R&D expenses surged to $3 million, reflecting ongoing investment in therapeutic development. The company expects funding will last through Q1 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
none
Transcode Therapeutics Inc

Nasdaq:RNAZ

RNAZ Rankings

RNAZ Stock Data

7.00M
23.31M
0.01%
22.36%
77.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON